Pfizer Inc. expects its Covid-19 vaccine to hold up against the omicron variant, an executive said, and data on how well it protects should be available within two to three weeks.
“We don’t expect that there will be a significant drop in effectiveness,” Ralf Rene Reinert, vice president of vaccines for international developed markets, said in an interview with Bloomberg Television. “But again, this is speculation. We will check this. We will have the data in the next couple of weeks.”
